Our story begins with a meeting back in 2011 between the founders, Oren Goldshtein and Dr. Eyal Orion, MD. The two of them identified the existing heart failure management as a clear unmet clinical need and tried to imagine the next stage of implantable hemodynamic monitoring, without limiting themselves with technological and medical constraints. At that time, the only way to really understand what was happening in the patient’s heart was to insert a catheter with a pressure sensing tip inside a hospital environment, which proved costly and impractical.
What if there is a way to harness technology so that we can have the most accurate and specific physiological indication available daily and remotely at home?
Utilizing and weaving together their professional backgrounds, they conceived of the V-LAP to remotely monitor the heart’s left atrial pressure. With this foresight, our team understands the power of bringing digitally generated data from the heart and using AI-based analysis to improve treatment decisions and outcomes for patients suffering from heart failure.
Fast forward to the present day, and Vectorious’ team has successfully implanted in-heart micro computers in multiple countries across Europe and Israel. Our clinical study has been demonstrated huge potential in helping millions of people living with heart failure to take control and manage their disease, keeping them stable, out of hospitals, and living longer, fuller lives.
Every patient with chronic heart disease, will be remotely monitored by in-body micro-sensors.
This would enable a personalized, data driven treatment, at the convenience of the patient's home and would halt the disease’s deterioration.
We are on a mission of harvesting pressure data from the heart remotely with the world's first in-heart microcomputer.
Based on this data we will be providing valuable insights that will help caregivers make informed decisions to halt heart failure progression.
CEO & Co-Founder
Before co-founding Vectorious in 2011, Oren served in both managerial and lead-engineer positions in semiconductor and telecommunications businesses including CopperGate Communications (acquired by Sigma Designs USA), Amimon, and Metalink (acquired by Lantiq, Germany). Through these roles, Oren gained experience in all aspects of company building, technology innovation, implementation, and commercialization.
Oren holds an MSc and a BSc in Electrical Engineering from the Technion, Israel Institute of Technology.
Eyal is a serial entrepreneur and CEO of Vascular Graft Solutions (VGS) which provides cardiovascular surgery solutions.
Eyal Holds BSc (Med) from Technion, Israel Institute of Technology.
Dedi has accumulated extensive experience in the professional leadership of clinical studies, both in terms of design and execution. Before joining Vectorious, Dedi served as Clinical Trials Manager and Clinical Specialist at Paieon Medical and Senior Product Manager at Volcano Corporation with a focus on structural heart disease procedures such as TAVI and CRT. For V-Wave, a biomedical startup, in the field of heart failure, Dedi worked in close contact with heart failure specialists, overcoming all regulatory issues linked to the clinical aspects of the product deployment.
Dedi holds a BSc in Biotechnology engineering from the Ben Gurion University of the Negev and an MBA from the Recanati Business school, Tel Aviv University.
Before joining Vectorious in 2017, Matan served for seven years in the technological unit of the IDF Intelligence Corps, a position in which he developed expertise in a variety of disciplines within electronic engineering, including magnetic fields, RF and energy circuits. Matan was released as a major after completing a term as a group manager of automation engineers leading multiple critical projects within tight time constraints.
Matan holds a BSc in physics and a BSc in electrical engineering from the Technion, Israel institute of Technology.
Leor is an attending interventional cardiologist at the Rabin Medical Center in Israel and the director of the medical center’s innovation laboratory, where he teaches and guides entrepreneurs in their attempts to solve unmet clinical needs. Before that, he was the first Israeli physician to train at the prestigious Stanford University interventional cardiology fellowship, as well as to join the year-long Stanford Biodesign innovation fellowship.
Leor holds a BSc (Med) and an MD from the Hebrew University of Jerusalem.
Head of Marketing
Keren joined Vectorious in 2018 after working in senior marketing roles for several companies, including Gett, CEVA (NASDAQ: CEVA), and Microsoft. She also has a rich background in Journalism (TV correspondence and researcher) - which makes the written word and storytelling her passion.
Keren holds an MA from Tel Aviv University, as well as an MBA from The College of Management - Academic Studies (COMAS).
Professor Di Mario is Professor of Cardiovascular Medicine and Director of Structural Interventional Cardiology at Careggi University Hospital in Florence, Italy, and Honorary Consultant in Interventional Cardiology at Royal Brompton Hospital, in London, England.
Prior to this, he was the President of the European Association of Cardiovascular Interventions of the European Society of Cardiology and President-Elect of the EuroCTO Club. Internationally regarded as an expert in his field, Professor Di Mario Prior also serves on the editorial board of leading academic journals.
Professor Abraham (MD, FACP, FACC. FAHA, FESC, FRCPE) is the College of Medicine Distinguished Professor and Professor of Medicine, Physiology, and Cell Biology at The Ohio State University. Internationally-known as a heart failure expert and researcher, Professor Abraham has been a primary investigator in landmark studies in the field, including the pivotal study of the CardioMEMS system.
Prior to his work at Charité, Professor Anker served as an Innovative Clinical Trials (W3) at University Medical Center Göttingen. He is Councilor of the Board European Society of Cardiology (ESC, 2014-16).
Since 2006, he has been a board member of the Heart Failure Association (HFA) of the ESC, additionally, serving as its President from 2012-14 and is now chairing its Committee on Regulatory Affairs. He is also the founding editor-in-chief of ESC Heart Failure, the first open access heart failure journal, and serves on the editorial boards of five scientific journals, including European Heart Journal, European Journal of Heart Failure and IJC.
Dr. Sievert is the Director of the CardioVascular Center Frankfurt and a Professor at the University of Frankfurt. In addition, he serves as an honorary professor and a visiting professor at leading universities in the UK, USA, and China, too.
Dr. Sievert has been the principal investigator of many clinical trials in the field of interventional cardiology and has authored more than 300 manuscripts and 700 abstracts in peer-reviewed journals, 125 books and book contributions. He is a member of the editorial council at several prestigious medical journals.
Vectorious is always on the lookout for top talent. If you have passion and a big heart, check out our open positions and apply.
Subscribe to get Vectorious' Newsletter with the latest news and clinical updates from the VECTOR-HF study